May 24, 2024 · Form 4 insider transaction
Kewalramani Reshma sold 1,565 shares of Vertex Pharmaceuticals Incorporated at $457.00 per share, a transaction worth $715.2K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 5 days after the transaction.
Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 02/07/2024.